# Novo Nordisk to acquire controlling stake in BIOCORP

Novo Nordisk entered exclusive negotiations to acquire a controlling stake in BIOCORP, a French medical device company, from main shareholder BIO JAG, representing 45.3% of share capital, at €35 per share. This will be followed by a mandatory tender offer for all remaining shares, valuing BIOCORP at approximately €154 million.

- Type: Acquisition
- Announced: 2023-06-05
- Where: Issoire, France
- Value: $165.0M (154.0M EUR)
- Status: announced
- Products: delivery systems, medical devices, Mallya smart add-on device for pen injectors
- Sectors: [Medical Devices](https://endata.com/sectors/medical-devices.md)

## Companies

- [Novo Nordisk](https://endata.com/companies/17868.md) (acquirer)
- [BIOCORP Production](https://endata.com/companies/70665.md) (target)

## Sources

- [globenewswire.com](https://www.globenewswire.com/news-release/2023/06/05/2681613/0/en/novo-nordisk-enters-exclusive-negotiations-to-acquire-a-controlling-stake-in-biocorp-to-be-followed-by-a-tender-offer-on-all-remaining-shares.html), 2023-06-05: "Novo Nordisk has entered into exclusive negotiations with BIO JAG, BIOCORP’s main shareholder, for the purchase of its entire stake in BIOCORP."

---
Data from Endata (https://endata.com/). Announcements are summarized from public sources and may be incomplete; check the linked originals.